Latest Breaking News On - Autosomal dominant polycystic kidney disease - Page 19 : vimarsana.com

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study - - Discontinuation of lixivaptan development expected to significantly

United statesCity ofUnited kingdomSaurabh sahaKristenk sheppardExchange commissionCentessa pharmaceuticalsAutosomal dominant polycystic kidney diseaseChief executive officerQuarterly report

Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United statesCity ofUnited kingdomSaurabh sahaKristenk sheppardExchange commissionResearch developmentCentessa pharmaceuticalsCentessa pharmaceuticals makes strategic decisionDiscontinue clinical developmentAutosomal dominant polycystic kidney diseaseChief executive officerQuarterly reportVice president investorInvestegate announcementsInvestegate company announcements

Form 10-Q Centessa Pharmaceuticals For: Mar 31

Form 10-Q Centessa Pharmaceuticals For: Mar 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesJosh hamermeshPearlriver bio gmbCentessa subsidiariePearlriver bioDavid graingerJavad shahidiImgatuzumab pegaLixivaptan palladioAntoine yverIndex ventures life vi jerseyDevelopment accrualsPalladio biosciences incResearch developmentCentessa predecessor group

Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoOleg butovskyHowardl weinerJay haganCompany collaborationRnas the company or regulusRegulus therapeutics incDrug administrationExchange commissionDevelopment rd expensesProgram updatesInvestigational new drugAutosomal dominant polycystic kidney diseaseAmyotrophic lateral sclerosisAlport syndrome

Regulus Therapeutics (RGLS) Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics (RGLS) Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJay haganRnas the company or regulusRegulus therapeutics incDrug administrationInvestigational new drugAutosomal dominant polycystic kidney diseaseChief executive officer